Generate Biomedicines is a Biotechnology founded in 2018, currently valued at $1.2B. IPO Status: Pre-IPO (monitoring). IPO Readiness Score: 56/100 (C-).
Generate Biomedicines IPO status, timeline, valuation and S-1 filing tracker. Last updated May 2026.
| Industry | Biotechnology |
| Stage | Series A |
| IPO Status | Private |
| Valuation | $1.2B |
| Total Funding | $150M |
| Headquarters | Cambridge, MA |
| IPO Readiness Score | 56/100 |
| Founded | 2018 |
Track Generate Biomedicines IPO status, valuation updates, and S-1 filing milestones on TechStackIPO. Last updated May 2026.
AI-first drug company using generative biology to design novel protein therapeutics.
Generate Biomedicines is currently a private company being monitored by TechStackIPO for potential IPO activity. The company’s IPO readiness score is 56/100. Companies in the Biotechnology sector have seen significant IPO activity in recent years, with several notable listings and S-1 filings tracked on TechStackIPO. Key factors that could accelerate Generate Biomedicines’s path to IPO include revenue growth, profitability milestones, favorable market conditions, and strategic investor interest.
Generate Biomedicines is valued at $1.2B based on the most recent private market data. The company has raised a total of $150M in funding. Private market valuations are determined by the latest funding round and may differ from eventual IPO pricing, which reflects public market conditions, investor demand, and comparable company multiples at the time of listing.
Accredited investors may be able to access Generate Biomedicines pre-IPO shares through secondary market platforms. These platforms facilitate private share transactions between existing shareholders (employees, early investors) and new buyers.
Risk factors: Pre-IPO investments are illiquid, carry higher risk than public market investments, and are typically restricted to accredited investors. Share availability and pricing depend on current shareholders willing to sell. TechStackIPO provides data and tracking tools but does not facilitate or recommend investments.
Funding rounds from seed through latest — Series A, B, C and beyond.
| Round | Date | Amount | Valuation | Lead Investor(s) |
|---|---|---|---|---|
| Seed | Jul 2018 | $25M | $150M | ARCH Venture Partners |
| Series A | Dec 2021 | $150M | $1.2B | ARCH Venture Partners, Foresite Capital |
Total funding raised: $150M
Bear / base / bull scenarios based on current private market valuation and comparable IPO multiples.
| Scenario | Est. Valuation | Basis |
|---|---|---|
| Bear | $1.9B | Compressed multiples, delayed listing |
| Base | $1.2B | Last private round valuation |
| Bull | $3.5B | Strong market, premium AI/tech multiple |
Estimates are illustrative. Not investment advice. All figures based on publicly available data.
Generate Biomedicines has an IPO readiness score of 56/100 on TechStackIPO. A moderate readiness score suggests the company may be 2–4 years from IPO.
Generate Biomedicines's last known private valuation is $1.2B. IPO valuations typically reflect current market conditions at time of listing and may differ from private market valuations.
Pre-IPO access options may include: (1) secondary market platforms such as Forge Global or EquityZen that facilitate private share sales, (2) ETFs holding pre-IPO companies or venture portfolios, and (3) direct secondary share purchases if eligible as an accredited investor. TechStackIPO tracks availability but does not facilitate investments.
No. Generate Biomedicines has not yet filed an S-1 registration statement with the SEC as of TechStackIPO's latest data update.
Generate Biomedicines operates in the Biotechnology sector. TechStackIPO tracks multiple Biotechnology companies from seed through IPO, including their funding rounds, valuations, and IPO readiness scores. You can compare Generate Biomedicines against other Biotechnology companies using TechStackIPO's comparison tool.
Generate Biomedicines is at the Series A stage. The company has raised a total of $150M in funding. Companies at this funding stage are typically scaling operations, expanding market share, and evaluating public market timing.
Generate Biomedicines is headquartered in Cambridge, MA. The company's location can influence IPO exchange selection, regulatory requirements, and investor interest. Companies headquartered in major tech hubs often benefit from proximity to venture capital networks and talent pools.